60 related articles for article (PubMed ID: 38637772)
21. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial.
Parikh AR; Szabolcs A; Allen JN; Clark JW; Wo JY; Raabe M; Thel H; Hoyos D; Mehta A; Arshad S; Lieb DJ; Drapek LC; Blaszkowsky LS; Giantonio BJ; Weekes CD; Zhu AX; Goyal L; Nipp RD; Dubois JS; Van Seventer EE; Foreman BE; Matlack LE; Ly L; Meurer JA; Hacohen N; Ryan DP; Yeap BY; Corcoran RB; Greenbaum BD; Ting DT; Hong TS
Nat Cancer; 2021 Nov; 2(11):1124-1135. PubMed ID: 35122060
[TBL] [Abstract][Full Text] [Related]
22. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions.
Yi M; Zheng X; Niu M; Zhu S; Ge H; Wu K
Mol Cancer; 2022 Jan; 21(1):28. PubMed ID: 35062949
[TBL] [Abstract][Full Text] [Related]
23. Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial.
Siva S; Bressel M; Wood ST; Shaw MG; Loi S; Sandhu SK; Tran B; A Azad A; Lewin JH; Cuff KE; Liu HY; Moon D; Goad J; Wong LM; LimJoon M; Mooi J; Chander S; Murphy DG; Lawrentschuk N; Pryor D
Eur Urol; 2022 Apr; 81(4):364-372. PubMed ID: 34953600
[TBL] [Abstract][Full Text] [Related]
24. Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis.
Edeline J; Lamarca A; McNamara MG; Jacobs T; Hubner RA; Palmer D; Groot Koerkamp B; Johnson P; Guiu B; Valle JW
Cancer Treat Rev; 2021 Sep; 99():102258. PubMed ID: 34252720
[TBL] [Abstract][Full Text] [Related]
25. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
Zhu X; Cao Y; Liu W; Ju X; Zhao X; Jiang L; Ye Y; Jin G; Zhang H
Lancet Oncol; 2021 Aug; 22(8):1093-1102. PubMed ID: 34237249
[TBL] [Abstract][Full Text] [Related]
26. Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Benson AB; D'Angelica MI; Abbott DE; Anaya DA; Anders R; Are C; Bachini M; Borad M; Brown D; Burgoyne A; Chahal P; Chang DT; Cloyd J; Covey AM; Glazer ES; Goyal L; Hawkins WG; Iyer R; Jacob R; Kelley RK; Kim R; Levine M; Palta M; Park JO; Raman S; Reddy S; Sahai V; Schefter T; Singh G; Stein S; Vauthey JN; Venook AP; Yopp A; McMillian NR; Hochstetler C; Darlow SD
J Natl Compr Canc Netw; 2021 May; 19(5):541-565. PubMed ID: 34030131
[TBL] [Abstract][Full Text] [Related]
27. The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma.
Fiste O; Ntanasis-Stathopoulos I; Gavriatopoulou M; Liontos M; Koutsoukos K; Dimopoulos MA; Zagouri F
Vaccines (Basel); 2021 Apr; 9(5):. PubMed ID: 33922362
[TBL] [Abstract][Full Text] [Related]
28. Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma.
Zhang W; Yan C; Gao X; Li X; Cao F; Zhao G; Zhao J; Er P; Zhang T; Chen X; Wang Y; Jiang Y; Wang Q; Zhang B; Qian D; Wang J; Zhou D; Ren X; Yu Z; Zhao L; Yuan Z; Wang P; Pang Q
Oncologist; 2021 Jul; 26(7):e1110-e1124. PubMed ID: 33893689
[TBL] [Abstract][Full Text] [Related]
29. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Sung H; Ferlay J; Siegel RL; Laversanne M; Soerjomataram I; Jemal A; Bray F
CA Cancer J Clin; 2021 May; 71(3):209-249. PubMed ID: 33538338
[TBL] [Abstract][Full Text] [Related]
30. The Evolving Role of Radiation Therapy in the Treatment of Biliary Tract Cancer.
Gkika E; Hawkins MA; Grosu AL; Brunner TB
Front Oncol; 2020; 10():604387. PubMed ID: 33381458
[TBL] [Abstract][Full Text] [Related]
31. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Marabelle A; Fakih M; Lopez J; Shah M; Shapira-Frommer R; Nakagawa K; Chung HC; Kindler HL; Lopez-Martin JA; Miller WH; Italiano A; Kao S; Piha-Paul SA; Delord JP; McWilliams RR; Fabrizio DA; Aurora-Garg D; Xu L; Jin F; Norwood K; Bang YJ
Lancet Oncol; 2020 Oct; 21(10):1353-1365. PubMed ID: 32919526
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies.
Piha-Paul SA; Oh DY; Ueno M; Malka D; Chung HC; Nagrial A; Kelley RK; Ros W; Italiano A; Nakagawa K; Rugo HS; de Braud F; Varga AI; Hansen A; Wang H; Krishnan S; Norwood KG; Doi T
Int J Cancer; 2020 Oct; 147(8):2190-2198. PubMed ID: 32359091
[TBL] [Abstract][Full Text] [Related]
33. A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.
Kim RD; Chung V; Alese OB; El-Rayes BF; Li D; Al-Toubah TE; Schell MJ; Zhou JM; Mahipal A; Kim BH; Kim DW
JAMA Oncol; 2020 Jun; 6(6):888-894. PubMed ID: 32352498
[TBL] [Abstract][Full Text] [Related]
34. Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Cercek A; Boerner T; Tan BR; Chou JF; Gönen M; Boucher TM; Hauser HF; Do RKG; Lowery MA; Harding JJ; Varghese AM; Reidy-Lagunes D; Saltz L; Schultz N; Kingham TP; D'Angelica MI; DeMatteo RP; Drebin JA; Allen PJ; Balachandran VP; Lim KH; Sanchez-Vega F; Vachharajani N; Majella Doyle MB; Fields RC; Hawkins WG; Strasberg SM; Chapman WC; Diaz LA; Kemeny NE; Jarnagin WR
JAMA Oncol; 2020 Jan; 6(1):60-67. PubMed ID: 31670750
[TBL] [Abstract][Full Text] [Related]
35. Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Edeline J; Touchefeu Y; Guiu B; Farge O; Tougeron D; Baumgaertner I; Ayav A; Campillo-Gimenez B; Beuzit L; Pracht M; Lièvre A; Le Sourd S; Boudjema K; Rolland Y; Boucher E; Garin E
JAMA Oncol; 2020 Jan; 6(1):51-59. PubMed ID: 31670746
[TBL] [Abstract][Full Text] [Related]
36. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432.
Wang F; Wei XL; Wang FH; Xu N; Shen L; Dai GH; Yuan XL; Chen Y; Yang SJ; Shi JH; Hu XC; Lin XY; Zhang QY; Feng JF; Ba Y; Liu YP; Li W; Shu YQ; Jiang Y; Li Q; Wang JW; Wu H; Feng H; Yao S; Xu RH
Ann Oncol; 2019 Sep; 30(9):1479-1486. PubMed ID: 31236579
[TBL] [Abstract][Full Text] [Related]
37. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
Ueno M; Ikeda M; Morizane C; Kobayashi S; Ohno I; Kondo S; Okano N; Kimura K; Asada S; Namba Y; Okusaka T; Furuse J
Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):611-621. PubMed ID: 31109808
[TBL] [Abstract][Full Text] [Related]
38. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma.
Bertuccio P; Malvezzi M; Carioli G; Hashim D; Boffetta P; El-Serag HB; La Vecchia C; Negri E
J Hepatol; 2019 Jul; 71(1):104-114. PubMed ID: 30910538
[TBL] [Abstract][Full Text] [Related]
39. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors.
Marcus L; Lemery SJ; Keegan P; Pazdur R
Clin Cancer Res; 2019 Jul; 25(13):3753-3758. PubMed ID: 30787022
[TBL] [Abstract][Full Text] [Related]
40. Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Samstein RM; Lee CH; Shoushtari AN; Hellmann MD; Shen R; Janjigian YY; Barron DA; Zehir A; Jordan EJ; Omuro A; Kaley TJ; Kendall SM; Motzer RJ; Hakimi AA; Voss MH; Russo P; Rosenberg J; Iyer G; Bochner BH; Bajorin DF; Al-Ahmadie HA; Chaft JE; Rudin CM; Riely GJ; Baxi S; Ho AL; Wong RJ; Pfister DG; Wolchok JD; Barker CA; Gutin PH; Brennan CW; Tabar V; Mellinghoff IK; DeAngelis LM; Ariyan CE; Lee N; Tap WD; Gounder MM; D'Angelo SP; Saltz L; Stadler ZK; Scher HI; Baselga J; Razavi P; Klebanoff CA; Yaeger R; Segal NH; Ku GY; DeMatteo RP; Ladanyi M; Rizvi NA; Berger MF; Riaz N; Solit DB; Chan TA; Morris LGT
Nat Genet; 2019 Feb; 51(2):202-206. PubMed ID: 30643254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
